Evommune Inc. (EVMN) is approaching pivotal catalysts, with two clinical trial data readouts expected in the first half of 2026. The company is advancing EVO301, a Phase 2a study in atopic dermatitis, and EVO756, a dose-ranging Phase 2b trial in chronic spontaneous urticaria, both targeting chronic inflammation.
Atopic dermatitis affects millions worldwide, and current therapies often fail to provide durable relief, positioning EVO301 as a potential novel option in this underserved space.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.